O‘ZBEK POPULYATSIYADA NOS III GENINING G894T POLIMORFIZMI VA REZISTENT ARTERIAL GIPERTENZIYA
##article.abstract##
Tadqiqot maqsadi: AGT genining T704C polimorfizmi va NOS3 genining G894T polimorfizmining O‘zbekiston aholisida rezistent arterial gipertenziya (RAG) rivojlanish xavfiga ta’sirini o‘rganish.
Sel issledovaniya: izuchit vzaimosvyaz G894T polimorfizma gena NOS3 s riskom razvitiya rezistentnoy arterialnoy gipertenzii (AG) v uzbekskoy populyatsii.
Materiallar va usullar: tadqiqot respublika ixtisoslashtirilgan kardiologiya ilmiy-amaliy tibbiyot markazida ambulator davolanayotgan, gipertoniya kasalligi I-III darajaci bilan og‘rigan 176 nafar bemorni qamrab oldi. DNKning qon tarkibidan «DiatomTM DNA Prep 200» («Laboratoriya IzoGen» MChJ, Rossiya) to‘plami yordamida ajratilgan. Izolyatsiya qilingan DNKning miqdori va sifati gel elektroforezi va NanoDrop (Thermo Scientific, AQSh)) spektrofotometri yordamida baholandi. NOSIII gen G894T (rs1799983) polimorfizmi allel va genga xos praymerlar va zondlar yordamida real vaqt rejimida polimeraz zanjir reaksiyasi yordamida aniqlandi.
Natijalar: genetik irsiyat modellaridan foydalangan holda tahlil qilish natijasida AGT genining T704C polimorfizmi alleli bilan rezistent arterial gipertenziya bilan bog‘liqligi va NOS3 genining G894T polimorfizmining polimorfizmining O‘zbekiston aholisida rezistent gipertenziya rivojlanish xavfiga nisbatan himoya ta’siri aniqlandi.
Xulosa: AGT genining T704C polimorfizmining C alleli va CC genotipi rezistent arterial gipertenziya bilan bog‘liq. NOS3 genining G894T polimorfizmining alleli G allelya i GG genotipini tashish O‘zbekiston aholisida rezistent gipertenziya rivojlanish xavfining pastligi bilan bog‘liq.
Библиографические ссылки
Owiredu, W.K.B.A.; Appiah, M.; Obirikorang, C.; Adu, E.A.; Boima, V.; Amos-Abanyie, E.K.; Akyaw, P.A.; Owiredu, E.-W.; Acheampong, E. Association of MYH9-rs3752462 polymorphisms with chronic kidney disease among clinically diagnosed hypertensive patients: A case-control study in a Ghanaian population. Clin. Hypertens. 2020, 26, 1–9.
Bloch, M.J. Worldwide prevalence of hypertension exceeds 1.3 billion. J. Am. Soc. Hypertens. 2016, 10, 753–754.
Sombié, H.K.; Kologo, J.K.; Tchelougou, D.; Ouédraogo, S.Y.; Ouattara, A.K.; Compaoré, T.R.; Nagalo, B.M.; Sorgho, A.P.; Nagabila, I.; Soubeïga, S.T.; et al. Positive association between ATP2B1 rs17249754 and essential hypertension: A case-control study in Burkina Faso, West Africa. BMC Cardiovasc. Disord. 2019, 19, 155.
Zhou, B.; Bentham, J.; Di Cesare, M.; Bixby, H.; Danaei, G.; Cowan, M.J.; Paciorek, C.J.; Singh, G.; Hajifathalian, K.; Bennett, J.E.; et al. Worldwide trends in blood pressure from 1975 to 2015: A pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet 2017, 389, 37–55.
Cheong, A.T.; Sazlina, S.G.; Tong, S.F.; Azah, A.S.; Salmiah, S. Poor blood pressure control and its associated factors among older people with hypertension: A cross-sectional study in six public primary care clinics in Malaysia. Malays. Fam. Phys. 2015, 10, 19–25.
Firmo, J.O.A.; Mambrini, J.V.d.M.; Peixoto, S.V.; Loyola Filho, A.I.d.; Souza Junior, P.R.B.d.; Andrade, F.B.d.; Lima-Costa, M.F. Adequate control of hypertension among older adults: ELSI-Brazil. Revista Saude Publica 2018, 52, 13s.
Pender, K.; Omole, O. Blood pressure control and burden of treatment in South African primary healthcare: A cross-sectional study. Afr. J. Prim. Health Care Fam. Med. 2019, 11, 7.
[Seedat, Y.; Rayner, B.; Veriava, Y. South African hypertension practice guideline 2014. Cardiovasc. J. Afr. 2014, 25, 288–294. [CrossRef] 9. Yaxley, J.P.; Thambar, S.V. Resistant hypertension: An approach to management in primary care. J. Fam. Med. Prim. Care 2015, 4, 193–199].
Kaplan N.M. Resistant hypertension// J.Hypertens. 2005. V. 23.P. 1441-1444
Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008 // Hypertension. 2011. V.57. P.1076-1080
Holecki M.,Dulawa J., Chulek J. Resistant hypertension in visceral obesity// Eur. J. Intern. Med. 2012. V. 23. P. 643-648
Bramalage P., Pittrow D., Witchen H.U. et.al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled // Am. J. Hypertens. 2004. V. 17. P. 904-910.
Jordan J., Yumuk V., Schlaich M. et al. Joint statement of the European association for the study of obesity and the European society of hypertension: obesity and difficult to treat arterial hypertension// J.Hypertens. 2012. V. 30. P. 1047-1055.
Engbaek M., Hjerrild M., Hallas J., Jacobsen I.A. The effect of low-dose spironolactone on resistance hypertension // J. Am. Soc. Hypertens. 2010. V. 4. 290-294.
Tsioufis C., Kordalis A., Flessas D. et al. Pathophysiology of resistance hypertension: the role of sympathetic nervous system // Int. J. Hypertens. 2011. doi: 10.4061/2011/642416.
Zatz R., Baylis C. Chronic nitric oxide inhibition model six years on // Hypertension. 1998. V. 32. P. 958-964.
Mabhida SE, Mashatola L, Kaur M, Sharma JR, Apalata T, Muhamed B, Benjeddou M Hypertension in African Populations: Review and Computational Insights., Johnson R.Genes (Basel). 2021 Apr 6;12(4):532.
Yasuo Takahashi1*, Keiko Yamazaki1,2, Yoichiro Kamatani3, Michiaki Kubo4,Koichi Matsuda5 & Satoshi Asai1,6.
Yugar-Toledo JC, Martin JF, Krieger JE, Pereira AC, Demacq C, Coelho OR, Pimenta E, Calhoun DA, Júnior HM. Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes.DNA Cell Biol. 2011 Aug;30(8):555-64. doi: 10.1089/dna.2010.1156. Epub 2011 Mar 27.
Schunkert H, Hense HW, Döring A, Riegger GA, Siffert W. Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension. 1998;32(3):510–3.
